ImmunityBio, Inc. (IBRX)
Healthcare
- Fundamental
- 2
- Sentiment
- 1
- Technical
- 2
Do Nothing: fundamentalScore 2 (below the required floor of 3) and qualitativeScore 1 (below the required floor of 3) hard-block any long entry; the chart is a bounce-only oversold downtrend (close 6.02 below SMA20 7.95, SMA50 8.59 and SMA200 7.97 with MACD -0.65 vs signal -0.38 and histogram -0.27 still widening), and neither entry type qualifies - no breakout stop above the settled 2026-11-13 high 6.17 (counter-trend into overhead supply at 6.50/6.85/8.69) and no pullback limit below the 2026-11-13 low 5.83 (a dip in a live downtrend with price < SMA50 and MACD < 0).
Company overview
ImmunityBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing therapies and vaccines for various cancers and infectious diseases. The company utilizes immunotherapy and cell therapy platforms and has several candidates in advanced clinical trials targeting tumors and pathogens like SARS-CoV-2 and HIV. It collaborates with organizations such as the National Cancer Institute and holds various licensing agreements.
Fundamental
weakImmunityBio's commercial progress is overshadowed by a high-risk, dilution-dependent capital structure and going-concern warnings.
Commercial inflection on an impaired balance sheet: revenue up 92% year-to-date with a new FDA label expansion, but explicit going-concern language, negative equity of $1.15B, negative operating cash flow and a $480M convertible note due December 2027 make this a high-risk, dilution-dependent story rather than a clean investment case.
Sentiment
very weakSentiment has cooled significantly, with media coverage reflecting mixed views and retail sentiment indeterminate.
Dominant catalyst is the 2026-11-09 Q3 2026 print — revenue and EPS miss, wider net loss and an explicit going-concern warning — which drove a roughly 15–20% drawdown despite same-day QUILT-2.005 registrational-endpoint and Israeli-approval positives (both announced, neither rewarded by the tape). The measured sentiment delta cooled from +0.28 (baseline) to +0.03 (scoring), retail is indeterminate (Reddit 403), and the severe going-concern red-flag cap applies, holding the qualitative read at the bottom of the scale; a conflicting-catalyst moderate cap (ceiling 3) also fires but is superseded.
Technical
weakThe technicals show a deeply oversold condition with no bullish confirmation, indicating a bounce-only scenario.
Chart is decisively bearish and the structure is broken. Last close 6.02 (2026-11-13) sits below the SMA20 7.95, SMA50 8.59, SMA200 7.97, EMA9 7.08 and EMA21 7.83, with the 50-day below the 200-day (8.59 vs 7.97) after a -30.3% five-session collapse from the 2026-11-06 close of 8.64 driven by the 2026-11-09 Q3 print. MACD is negative and deteriorating (line -0.65 vs signal -0.38, histogram -0.27 and widening over the last five sessions from -0.11), and ADX14 23.55 is rising while price is below every average - a strengthening DOWN trend, not a base. The only constructive read is deeply oversold oscillators (RSI14 32.59, Williams %R -93.91) with no confirmation whatsoever (no MA reclaim, no MACD turn), i.e. a bounce-only oversold condition inside a broken downtrend; that earns a chart score of 2, not more. ATR14 0.72 = 11.96% of price keeps volatility extreme, which is why the structure cannot support a tight stop. Independent of the chart, the action is Do Nothing on the override gates: fundamentalScore 2 (< 3) and qualitativeScore 1 (< 3).
You’re looking at 2026-11-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

